Brian Ingram, Director, Discovery & Translational Sciences at Metabolon Shares his Views on the Expansion of its Inflammation Portfolio

Shots:Brian briefed our readers about Metabolon’s inflammation portfolio expansion with the launch of new Targeted Panels studying cannabinoids, sphingolipids, and lipid mediators of inflammation including its Oxysterols Targeted PanelHe also talked about Endocannabinoids and Sphingolipids and how Metabolon targeted panels are used for their measurementsThe interview highlights how Metabolon’s mission to deliver…